ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection
ENHERTU is FDA-approved for the treatment of several types of cancer – HER2+ Metalistic Breast Cancer, HER2+ Low Metalistic Breast Cancer, HER2+ Advanced Breast Cancer,HER2+ Metalistic Lung Cancer.. Brand Name: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U.S. Approval: 2019
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions. We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection
Fam-trastuzumab deruxtecan-nxki is approved to treat adults with: Breast cancer, Gastric (stomach) cancer or gastroesophageal junction cancer (a rare type of esophageal cancer), Non-small cell lung cancer. Fam-trastuzumab deruxtecan-nxki is also being studied in the treatment of other types of cancer.
A drug used to treat adults with certain types of HER2-positive or HER2-low breast cancer, HER2-positive stomach cancer or gastroesophageal junction cancer, or non-small cell lung cancer that has a certain mutation in the HER2 gene. It is also being studied in the treatment of other types of cancer. Enhertu contains a monoclonal antibody called trastuzumab that binds to a protein called HER2, which is found on some cancer cells. It also contains an anticancer drug called deruxtecan, which may help kill cancer cells. Enhertu is a type of antibody-drug conjugate. Also called fam-trastuzumab deruxtecan and trastuzumab deruxtecan.
Fam-trastuzumab deruxtecan-nxki is a type of targeted therapy drug called an antibody–drug conjugate. Trastuzumab is a monoclonal antibody that is chemically linked to a drug called deruxtecan that blocks an enzyme called topoisomerase I. The monoclonal antibody binds to HER2, a protein found in large amounts on some cancer cells. The linked drug enters these cells, damaging their DNA and killing them. Fam-trastuzumab deruxtecan-nxki also induces a type of immune reaction that kills surrounding cells.
Drug (Brand / Generic): ENHERTU / fam-trastuzumab deruxtecan-nxki
Current Indications: Breast cancer, Gastric (stomach) cancer or gastroesophageal junction cancer (a rare type of esophageal cancer), Non-small cell lung cancer
Marketed by:: Daiichi Sankyo, Inc.
Approval Date: 2019
Dosage forms and strengths of ENHERTU (fam-trastuzumab deruxtecan-nxki).
For injection: 100 mg lyophilized powder in a single-dose vial.
Find Reference Updates
Full prescribing information [FDA]: Enhertu (fam-trastuzumab deruxtecan-nxki)
Manufacturer: Daiichi Sankyo, Inc., Dec. 2019
FDA Approves Enhertu for Unresectable or Pretreated Metastatic HER2-Positive Breast Cancer
AstraZeneca, Daiichi’s breast cancer drug gets broader U.S. approval
Enhertu approved in the EU for the treatment of HER2-positive metastatic breast cancer
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection”. Confirmation of the order for ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – ENHERTU
For personal use, get access to an imported medicines (unapproved drug in India) for breast cancer. On request, Anti-cancer medicines can be imported to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Karnataka, Bangalore, Bhopal, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Dispur, Guwahati, Dehradun, Lucknow, Surat, Nagpur, New Delhi, Pondichery, Pune, Itanagar, Bathinda, Thirunananthapuram, Visakhapatnam, Chandigarh, Faridabad, Gurgaon, Agartala, Shillong, Goa, Wardha, Shimla, Dharamshala, Aizawl, Noida, Ghaziabad, Punjab.
ENHERTU Sourcing & Delivery
Alleviare India specializes in sourcing and supplying Enhertu Injection, a cancer treatment medicine, from around the world. They offer worldwide access to the best available treatment options. Alleviare India can dispense any valid prescription quickly and helps connect patients with potential distributors, wholesalers, suppliers, and dealers of Enhertu in India.
How much does Enhertu cost in the India?
Kindly reach out to us for ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
What documents are required to import ENHERTU to India?
To import trastuzumab deruxtecan Enhertu, patients or government hospitals can place an order on behalf of the patients. The following documentation is required for the import process:
- Valid prescription from a qualified doctor.
- Patients’ diagnostic reports.
- Patients’ ID proof issued by the Government of India.
The order will be confirmed only after the receipt of the following:
- Valid prescription from the doctor.
- Import permit, if applicable.
Please ensure that all the necessary documentation is provided to confirm the order.
Is ENHERTU available in India?
Enhertu famtrastuzumab deruxtecan nxki for injection is a prescription medication, which means it legally requires a medical prescription to be dispensed. Alleviare India assists in importing cancer medicines through the named patient supply (NPS) program. They provide information on the availability and prices of medications in various cities in India, such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune. Alleviare ensures 100% transparency and helps find genuine and reliable sources from Canada, Europe, USA, and Australia. They can facilitate the supply of ENHERTU (prescription medicines) to locations worldwide, including India, while ensuring compliance with legal requirements.
Please contact or mail @ – info@alleviareindia.com +91 9289711087 / 9289711088 for Enhertu availability and prices in India. We guarantee the authenticity and quality of our products and offer worldwide delivery according to the buyer’s specifications.
Is trastuzumab available in India?
Fam-trastuzumab deruxtecan nxki for injection is used in the treatment of a particular type of breast cancer — HER2-positive, and the company markets its version in India under the brand name ‘Trumab’.
How overseas patient can get access?
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
